SCHEMBL62885

SCHEMBL62885

COC(=O)c1c(C)[nH]c(=O)[nH]c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.50
NR4A2 P43354 1/20 0.46
ALDH1A1 P00352 5/20 0.45
KMT2A Q03164 4/20 0.45
LMNA P02545 4/20 0.45
POLB P06746 1/20 0.45
CYP1A2 P05177 1/20 0.43
USP2 O75604 1/20 0.42
RAB9A P51151 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 2/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8545504 0.81 HPGD (0.56) ALDH1A1KMT2ALMNAPOLBCYP1A2
SCHEMBL7252333 0.78 SMN1; SMN2 (0.45) NPSR1NR4A2ALDH1A1KMT2ALMNA
SCHEMBL27905866 0.77 CYP1A2 (0.48) NPSR1ALDH1A1KMT2ACYP1A2L3MBTL1
SCHEMBL27436337 0.77 NPC1 (0.48) NPSR1ALDH1A1KMT2ALMNACYP1A2
SCHEMBL7250696 0.76 USP2 (0.40) NPSR1NR4A2ALDH1A1KMT2ALMNA
SCHEMBL6699250 0.75 NPC1 (0.43) NPSR1ALDH1A1KMT2APOLBCYP1A2
SCHEMBL5419895 0.75 GAA (0.46) NPSR1NR4A2ALDH1A1KMT2ALMNA
SCHEMBL13488596 0.72 NPSR1 (0.66) NPSR1NR4A2ALDH1A1KMT2ALMNA
SCHEMBL12364192 0.72 L3MBTL1 (0.46) NPSR1ALDH1A1KMT2ALMNACYP1A2
SCHEMBL7290595 0.71 NPSR1 (0.53) NPSR1NR4A2ALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 US disclosed
US-20220306634-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA SAN DIEGO, INC. 2022-09-29 US disclosed
EP-4019518-A1 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2022-06-29 EP disclosed
EP-3110820-B1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI INC (US) 2022-04-06 EP disclosed
EP-3825316-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2021-05-26 EP disclosed
EP-3825316-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2021-05-26 EP disclosed
EP-3489236-B1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICALS CO (JP) 2020-09-30 EP disclosed
EP-3489236-B1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICALS CO (JP) 2020-09-30 EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 EP disclosed
CN-1890263-A Tumour suppressor protein LUDWIG INST CANCER RES (CH) 2007-01-03 CN disclosed
CN-1890385-A Genes associated with colorectal cancer UNIV SHEFFIELD (GB) 2007-01-03 CN disclosed
CN-1860242-A Self-hybridizing multiplex target nucleic acid probes and methods of use thereof DYNAL BIOTECH INC (US) 2006-11-08 CN disclosed
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-12-15 US disclosed
WO-2005110416-A2 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES NEUROGEN CORPORATION (US) 2005-11-24 WO disclosed
CN-1628168-A Methods and materials for the production of organic products in cells of dollar i(candida) species CARGILL DOW POLYMERS LLC (US) 2005-06-15 CN disclosed
CN-1575340-A Compositions and methods for treating neurodegenerative diseases TANABE SEIYAKU CO (JP) 2005-02-02 CN disclosed
CN-1566366-A Genotype assignment method based on DNA chip and use thereof UNIV TSINGHUA (CN) 2005-01-19 CN disclosed
CN-1463270-A Cytotoxins, prodrugs, linkers and stabilizers useful therefor MEDAREX INC (US) 2003-12-24 CN disclosed
CN-1171112-A Amino acid nucleic acids ICN PHARMACEUTICALS CO (US) 1998-01-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C3AR1, C5AR1 NPSR1 220/4885NR4A2 241/4885ALDH1A1 1616/4885
US-20220306634-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN NPSR1 1144/4885NR4A2 1928/4885ALDH1A1 824/4885
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN NPSR1 1144/4885NR4A2 1928/4885ALDH1A1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.